Questions About Cancer? 1-800-4-CANCER
NCI Cancer Center News

Michigan study finds new drug cuts risk of deadly transplant side effect in half

  • Posted: December 10, 2012

A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center. The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 21 percent of patients developing going to a new website graft-vs.-host disease compared to 42 percent of patients who typically develop this condition with standard medications alone.

Click here to read full press release.

###

NCI comprehensive cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.